Synthesis and anticonvulsant activity of 3-(6-substituted-benzothiazol-2-yl)-6-phenyl-[1,3]-oxazinane-2-thiones

Archiv der Pharmazie

Volumn 335, Issue 8, 2002, Pages 381-388

  Chopade, Rajendra S ^a   Bahekar, Rajesh H ^d   Khedekar, Pramod B ^b   Bhusari, Kishore P ^b   Rao, Akkinpalli Raghu Ram ^c  

^a RTM NAGPUR UNIVERSITY   (India)

^b Nagar Yuwak Shikshan Sanstha   (India)

^c KAKATIYA UNIVERSITY   (India)

^d Franklin Wilkin's Building ^*  (United Kingdom)

Author keywords

3 (Benzothiazol 2 yl) 6 phenyl 1,3 oxazinane 2 thiones; Anticonvulsant; Maximal Electroshock Seizures (MES); Neurotoxicity; Subcutaneous pentylenetetrazole (sc PTZ); Synthesis

Indexed keywords

3 (6 DIMETHYLAMINOBENZOTHIAZOL 2 YL) 6 PHENYL 1,3 OXAZINANE 2 THIONE; 3 (BENZOTHIAZOL 2 YL) 6 PHENYL 1,3 OXAZINANE 2 THIONE; OXAZINE DERIVATIVE; PENTETRAZOLE; PHENYTOIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG PENETRATION; DRUG STRUCTURE; ELECTRIC SHOCK; LIPOPHILICITY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SEIZURE;

EID: 0036803927     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4184(200211)335:8<381::AID-ARDP381>3.0.CO;2-S     Document Type: Article

References (20)

1. nd Ed (Ed: D. M. Woodbury, J. K. Penry, C. E. Pippenger), Reven Press, New York 1982, pp. 5-20.
2. W. Loscher, D. Schmidt, Epilepsy Res. 1994, 17, 95-134.
3. J. O. McNamara in The Pharmacological Basis of Therapeutics, 9th Ed (Ed: J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, A. G. Gilman), McGraw Hill, New York, 1990, pp. 461-486.
4. Z. Lin, P. K. Kadaba, Med. Res. Rev. 1997, 17, 537-572.
5. J. F. Wolfe, T. D. Greenwood, J. M. Mulheron, Exp. Opin. Ther. Patents 1998, 8, 361-381.
6. N. D. P. Cosford, I. A. McDonald, E. J. Schweiger, Annu. Rep. Med. 1998, 33, 61-70.
7. S. J. Hays, M. J. Rice, D. F. Ortwine, G. Johnson, R. D. Schwarz, D. K. Boyd, L. F. Copeland, M. G. Vartanian, P. A. Boxer, J. Pharm. Sci. 1994, 83, 1425-1432.
8. J. Mizoule, B. Meldrum, M. Martine, M. Croucher, C. Ollak, A. Uzan, J. J. Legrand, C. Gueremy, G. LeFur, Neuropharmacology, 1985, 24, 767-773.
9. J. Benavides, J. C. Camelin, N. Mitrani, F. Flamand, A. Uzan, J. J. Legrand, C. Gueremy, G. LeFur, Neuropharmacology 1985, 24, 1085-1092.
10. st National ACS Meeting. Atlanta, GA, MEDI 6, 1991.
11. D. S. Ragsdale, T. Scheuer, W. A. Catterall, Mol. Pharmacol. 1991, 40, 756-765.
12. C. Singh, H. K. Parwana, G. Singh, Indian J. Pharm. Sci. 1995, 57, 198.
13. P. B. Khedekar, K. P. Bhusari, R. H. Bahekar, A. R. R. Rao, S. N. Umathe, Indian J. Heterocycl Chem. 2001, 10, 231-234.
14. P. B. Khedekar, K. P. Bhusari, R. H. Bahekar, A. R. R. Rao, S. N. Umathe, Indian J. Heterocycl Chem. 2000, 9, 275-278.
15. P. B. Khedekar, K. P. Bhusari, R. H. Bahekar, A. R. R. Rao, S. N. Umathe, Indian J. Heterocycl Chem. 2000, 9, 213-216.
16. J. Trefouel, M. Trefouel, F. Nitti, D. Bovet, Chem. Res. Soc. Bio. 1935, 120, 756.
17. rd Ed. (Eds: R. H. Levy, F. C. Dreifuss, R. H. Mattson, B. S. Meldrum, J. K. Penry), Raven Press, New York, 1989, 85-102.
18. N. W. Dunham, T. S. Miya, J. Am. Pharmacol. Assoc. 1957, 46, 208-209.
19. C. Podesva, K. Vagi, Can. J. Chem. 1966, 44, 1872-1875.
20. J. Litchfield, F. Wilcoxon, J. Pharmacol. Exp. Ther. 1949, 96, 99-115.